how to buy digital currency People searches

Zheshang Securities: It does not rule out the possibility of lowering the RRR and cutting interest rates at the same time before the end of the year. Zheshang Securities research report said that this central economic work conference went further on the basis of the previous Politburo meeting, and clearly put forward "timely RRR reduction and interest rate reduction". Combined with the central bank's statement on the RRR reduction space in late September, it is expected that there will be a 50-basis-point RRR reduction before the end of the year, which will greatly promote interest rate reduction in the first quarter of next year, and even does not rule out the possibility of simultaneous RRR reduction and interest rate reduction before the end of the year. We are optimistic that the equity market and the bond market will step out of the double bull market in the process of gradual policy development.Solar energy and other new companies have set up photovoltaic power generation equipment business. The enterprise search APP shows that recently, China Energy Saving Ledebao Solar Technology (Delingha) Co., Ltd. was established, with Du Hu as the legal representative and a registered capital of 1 million yuan. Its business scope includes: sales of solar thermal utilization equipment; Lease of photovoltaic power generation equipment; Ecological restoration and ecological protection services, etc. Enterprise investigation shows that the company is jointly owned by China Energy Saving Solar Technology Co., Ltd. and Qinghai Laidebao New Materials Co., Ltd., a wholly-owned subsidiary of solar energy.Hong Kong stock Jingtai Holdings plunged nearly 15%, and the company's 1.464 million restricted shares are expected to circulate freely from today.

Japan's Topix index fell to 1%.Guojin Securities: The warm wind of medical policy comes first, then the progress of innovation going out to sea, and then the opportunity of performance reversal. Guojin Securities Research Report said that the core investment opportunities in the pharmaceutical sector in 25 years will revolve around three logics: 1) innovation going out to sea; 2) demand recovery; 3) Policy expectation reversal. At present, the policy warm wind comes first (the medical track policy continues to warm up, and the overall industry expectation is expected to be optimistic); Then, R&D and innovation will go to sea (innovative drug track will continue to make progress, and it will still be the hottest track in the pharmaceutical sector in 2025, especially it is recommended to pay attention to the clinical data reading and commercialization progress of the first-line target, as well as the fluctuation opportunity of the expected difference of the second-line innovative drugs), and then the performance growth rate is expected to bottom out in the first half of 2025 (but it will take time for this improvement in performance growth rate to come. Considering the current industry communication and historical base, it is expected that 4Q24 and 1Q25 should still be cautiously optimistic.)Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.

The vacancy of Cao Guo was filled. South Korea's opposition camp continued to maintain 192 seats in the National Assembly. On the 13th, local time, South Korea's Central Electoral Management Commission decided that Bai Xianji, the motherland reform party, would take over the vacancy of Cao Guo. As a result, South Korea's opposition camp continued to maintain 192 seats in the National Assembly. On the afternoon of the 12th, Cao Guo, the leader of South Korea's opposition party, the Motherland Reform Party, was found guilty of fraud in the final judgment of his children's education, and Cao Guo was immediately deprived of his qualification as a member of parliament. The total number of members of the opposition camp decreased from 192 to 191. (CCTV News)The consumer electronics sector fell in the short term, and the consumer electronics sector fell in the short term, and the victory precision fell. Fenda Technology, Bird, Darui Electronics, Chuanyi Technology and Guanghong Technology followed suit.The central bank's open market today launched a 7-day reverse repurchase operation of 205.1 billion yuan, and the operating interest rate was flat at 1.50%. Today, 190.9 billion yuan of 7-day reverse repurchase expired, and the net investment on that day was 14.2 billion yuan.